{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:20:35Z","timestamp":1787743235723,"version":"build-2784847793"},"reference-count":15,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"unspecified","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["24fk0108715h0001"],"award-info":[{"award-number":["24fk0108715h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,8,17]]},"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Older adults are at an increased risk of influenza-related hospitalisation and mortality due to a combination of risk factors. Severe influenza and excess mortality in this population remain major public health concerns, underscoring the need for novel treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This multicentre, investigator-initiated, randomised, double-blind clinical trial evaluated the efficacy and safety of the investigational drug favipiravir injection (T-705IV) in combination with oseltamivir phosphate, compared with oseltamivir monotherapy in hospitalised patients with influenza aged \u226565 years. Both T-705IV and oseltamivir phosphate will be administered for 5\u2009days. The primary endpoint is time from randomisation to recovery within 15 days. Recovery is defined as either actual hospital discharge or sustained clinical status permitting discharge for 3 consecutive days. Clinical status will be assessed using a 7-point ordinal scale based on hospitalisation status and oxygen requirement. The primary analysis employs a Bayesian Cox proportional hazards model with a non-informative prior to estimate the posterior probability that the HR exceeds 1.0. The secondary endpoints include the distribution of 7-point scale scores over a 29-day period; rates of clinical worsening at days 15 and 29; duration of fever; all-cause mortality; intensive care unit admission within 29 days; pneumonia complication rate at 15 days; and changes in viral titre and viral RNA load on days 1, 2, 3 and 7. Safety will be assessed through the collection of adverse events (AEs) up to day 29. Pharmacokinetic evaluation will include measurement of plasma favipiravir concentrations on day 3. The planned sample size is 80 patients (40 per group).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Written informed consent will be obtained from all participants. This study was approved by the Center Hospital of the National Center for Global Health and Medicine Institutional Review Board (approval number: NCGM-I-022-24a) and registered in the Japan Registry of Clinical Trials. Study findings will be disseminated through peer-reviewed publications and\/or presentations at academic conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>jRCT2031240586,<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-106715","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:40:25Z","timestamp":1787740825000},"page":"e106715","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Study protocol for a phase II clinical trial evaluating the safety and efficacy of favipiravir injection combined with oseltamivir in influenza treatment"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6495-0277","authenticated-orcid":false,"given":"Sayaka","family":"Hikida","sequence":"first","affiliation":[{"name":"Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Nomoto","sequence":"additional","affiliation":[{"name":"Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Uemura","sequence":"additional","affiliation":[{"name":"Laboratory of Biostatistics, Department of Data Science, Center for Clinical Sciences, Japan Institute for Health Security, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadaki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease Pathology, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan"},{"name":"Department of Infectious Disease Pathobiology, Graduate School of Medicine, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Izumikawa","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan"},{"name":"Infection Control and Education Center, Nagasaki University Hospital, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ohge","sequence":"additional","affiliation":[{"name":"Project Research Center for Nosocomial Infectious Diseases, Hiroshima University, Hiroshima, Japan"},{"name":"Department of Infectious Diseases, Hiroshima University Hospital, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Yamato","sequence":"additional","affiliation":[{"name":"Infectious Diseases Center, Rinku General Medical Center, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, International University of Health and Welfare Narita Hospital, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3135-1757","authenticated-orcid":false,"given":"Ryota","family":"Hase","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Japanese Red Cross Narita Hospital, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuji","family":"Aoyagi","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology and Infection, Tohoku University Graduate School of Medicine, Miyagi, Japan"},{"name":"Department of Clinical Infectious Diseases, Tohoku University Graduate School of Medicine, Miyagi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5086-1891","authenticated-orcid":false,"given":"Hideharu","family":"Hagiya","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Nukui","sequence":"additional","affiliation":[{"name":"Department of Infection Control & Laboratory Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Division of Infectious, Respiratory, and Digestive Medicine, University of the Ryukyus Graduate School of Medicine, Okinawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Takesue","sequence":"additional","affiliation":[{"name":"Chita Peninsula General Medical Organization, Rinku Hospital, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Sawada","sequence":"additional","affiliation":[{"name":"Laboratory of Biostatistics, Department of Data Science, Center for Clinical Sciences, Japan Institute for Health Security, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Laboratory of Biostatistics, Department of Data Science, Center for Clinical Sciences, Japan Institute for Health Security, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease Pathology, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan"},{"name":"Department of Infectious Disease Pathobiology, Graduate School of Medicine, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namiko","family":"Tamura","sequence":"additional","affiliation":[{"name":"Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozue","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Saito","sequence":"additional","affiliation":[{"name":"Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Center for Clinical Sciences, Japan Institute for Health Security, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Morino","sequence":"additional","affiliation":[{"name":"Center for Clinical Sciences, Japan Institute for Health Security, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Tokita","sequence":"additional","affiliation":[{"name":"Center for Clinical Sciences, Japan Institute for Health Security, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Ohmagari","sequence":"additional","affiliation":[{"name":"Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"2026082603401553000_16.8.e106715.1","unstructured":"Centers for Disease Control and Prevention (CDC) . People at higher risk of flu complications. Available: https:\/\/www.cdc.gov\/flu\/highrisk\/index.htm [Accessed 14 Aug 2024]."},{"key":"2026082603401553000_16.8.e106715.2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010481","article-title":"Preclinical and clinical developments for combination treatment of influenza","volume":"18","author":"Koszalka","year":"2022","journal-title":"PLoS Pathog"},{"key":"2026082603401553000_16.8.e106715.3","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-016-1383-8","article-title":"Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study","volume":"16","author":"Zhang","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2026082603401553000_16.8.e106715.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00469-2"},{"key":"2026082603401553000_16.8.e106715.5","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01739-09"},{"key":"2026082603401553000_16.8.e106715.6","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA) . \u201cAvigan tablet 200 mg: report on the results of deliberations. Available: https:\/\/www.pmda.go.jp\/files\/000210319.pdf [Accessed 1 May 2025]."},{"key":"2026082603401553000_16.8.e106715.7","doi-asserted-by":"publisher","DOI":"10.2217\/fvl.13.98"},{"key":"2026082603401553000_16.8.e106715.8","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00933-09"},{"key":"2026082603401553000_16.8.e106715.9","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz656"},{"key":"2026082603401553000_16.8.e106715.10","unstructured":"National Center for Global Health and Medicine (NCGM) . Infectious disease clinical research network with national repository. Available: https:\/\/nwp.ncgm.go.jp\/overview.html [Accessed 1 May 2025]."},{"key":"2026082603401553000_16.8.e106715.11","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA) . Rapiacta 300 mg infusion bag and 150 mg infusion vial: report on the results of deliberations. Available: https:\/\/www.pmda.go.jp\/drugs\/2010\/P201000001\/34001800_22200AMX00010_A100_1.pdf [Accessed 14 Nov 2024]."},{"key":"2026082603401553000_16.8.e106715.12","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz137","article-title":"Clinical Development of Therapeutic Agents for Hospitalized Patients With Influenza: Challenges and Innovations","volume":"6","author":"King","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2026082603401553000_16.8.e106715.13","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30483-7"},{"key":"2026082603401553000_16.8.e106715.14","doi-asserted-by":"crossref","first-page":"e4369","DOI":"10.1093\/cid\/ciaa777","article-title":"Development of an Ordinal Scale Treatment Endpoint for Adults Hospitalized With Influenza","volume":"73","author":"Lee","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026082603401553000_16.8.e106715.15","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.11150\/kansenshogakuzasshi1970.74.1044","article-title":"Clinical efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir in treating acute influenza--placebo-controlled double-blind multicenter phase III trial","volume":"74","author":"Kashiwagi","year":"2000","journal-title":"Kansenshogaku Zasshi"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-106715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:40:28Z","timestamp":1787740828000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-106715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":15,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,26]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1136\/bmjopen-2025-106715"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-106715","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}